Consolidated Statements of Changes in Equity $ in Thousands |
USD ($)
shares
|
Opening balance after adjustment, cumulative effect at date of initial application
USD ($)
|
Share capital
USD ($)
shares
|
Share capital
Opening balance after adjustment, cumulative effect at date of initial application
USD ($)
shares
|
Contributed surplus
USD ($)
|
Contributed surplus
Opening balance after adjustment, cumulative effect at date of initial application
USD ($)
|
Accumulated deficit
USD ($)
|
Accumulated deficit
Opening balance after adjustment, cumulative effect at date of initial application
USD ($)
|
Foreign currency reserve
USD ($)
|
Foreign currency reserve
Opening balance after adjustment, cumulative effect at date of initial application
USD ($)
|
DSUs
USD ($)
|
DSUs
Share capital
USD ($)
shares
|
DSUs
Contributed surplus
USD ($)
|
RSUs
USD ($)
shares
|
RSUs
Share capital
USD ($)
shares
|
RSUs
Contributed surplus
USD ($)
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beginning balance (in shares) at Dec. 31, 2020 | shares | 282,078,177 | |||||||||||||||
Beginning balance at Dec. 31, 2020 | $ 900,887 | $ 1,884,735 | $ 290,761 | $ (1,275,516) | $ 907 | |||||||||||
Changes in Stock Holders Equity [Roll Forward] | ||||||||||||||||
Net loss | (114,233) | (114,233) | ||||||||||||||
Deferred share consideration related to acquisition (notes 7 & 21) | 4,851 | 4,851 | ||||||||||||||
Equity offerings (in shares) | shares | 14,870,000 | |||||||||||||||
Equity offerings (note 21) | $ 527,291 | $ 527,291 | ||||||||||||||
Redeemed/exercised (in shares) | shares | 549,281 | 549,281 | 46,388 | 156,449 | 156,449 | |||||||||||
Redeemed/exercised | $ 2,415 | $ 3,526 | (1,111) | $ (1,290) | $ 127 | $ (1,417) | $ (4,357) | $ 577 | $ (4,934) | |||||||
Share-based compensation (note 21) | 9,669 | 9,669 | 1,290 | $ 4,357 | ||||||||||||
Other comprehensive income (loss): | ||||||||||||||||
Defined benefit plan actuarial gain (note 20) | 2,170 | 2,170 | ||||||||||||||
Foreign currency translation for foreign operations | 814 | 814 | ||||||||||||||
Ending balance (in shares) at Dec. 31, 2021 | shares | 297,700,295 | |||||||||||||||
Ending balance at Dec. 31, 2021 | 1,328,217 | $ 1,328,217 | $ 2,416,256 | $ 297,819 | $ (1,387,579) | $ 1,721 | ||||||||||
Other comprehensive income (loss): | ||||||||||||||||
Onerous contracts provision (notes 4 & 18) | (1,200) | (1,200) | ||||||||||||||
Net loss | (173,494) | (173,494) | ||||||||||||||
Deferred share consideration related to acquisition (notes 7 & 21) | $ (20) | $ 1,762 | (1,782) | |||||||||||||
Deferred share consideration related to acquisition (in shares) | shares | 112,451 | |||||||||||||||
Equity offerings (in shares) | shares | 112,451 | |||||||||||||||
Redeemed/exercised (in shares) | shares | 304,635 | 304,635 | 58,990 | 217,832 | 217,832 | |||||||||||
Redeemed/exercised | $ 916 | $ 1,349 | (433) | (753) | $ 244 | $ (997) | $ (2,466) | $ 785 | $ (3,251) | |||||||
Share-based compensation (note 21) | 9,408 | 9,408 | $ 753 | $ 2,466 | ||||||||||||
Defined benefit plan actuarial gain (note 20) | 1,514 | 1,514 | ||||||||||||||
Foreign currency translation for foreign operations | (3,211) | (3,211) | ||||||||||||||
Ending balance (in shares) at Dec. 31, 2022 | shares | 298,394,203 | |||||||||||||||
Ending balance at Dec. 31, 2022 | 1,158,911 | $ 2,420,396 | $ 300,764 | $ (1,560,759) | $ (1,490) | |||||||||||
Other comprehensive income (loss): | ||||||||||||||||
Onerous contracts provision (notes 4 & 18) | $ (4,400) |